A single 90-minute session of Floatation-REST, which minimizes sensory input, reduces resting-state functional connectivity within and between posterior hubs of the default-mode network and somatomotor cortices extending into the posterior insula. A control condition of resting in a zero-gravity chair produced a similar pattern of reduced connectivity. The findings suggest that reducing nervous system stimulation is reflected by decreased connectivity in brain networks that construct and map the sense of self.
In a phase 2 randomized clinical trial, TSND-201 (methylone) reduced PTSD symptoms more than placebo in adults aged 18 to 65. Over 10 weeks, 65 participants received either TSND-201 or placebo in four weekly oral sessions. The drug group showed a significantly greater improvement in the primary measure of PTSD severity (CAPS-5) than placebo, with a difference of about 10 points. Secondary measures of PTSD-related distress, disability, and depression also improved more with the drug. Common side effects included headache, nausea, and increased blood pressure. The results suggest TSND-201 is a well-tolerated, rapid-acting treatment for PTSD.